Bladder cancer can be divided into molecular subtypes based on transcriptome profiling, which can precisely classify patients according to their prognosis and therapeutic options.[35, 40, 42] We found that the low S100A5 group patients were more likely to be the basal subtype, while those belonging to the high S1005A group could be the luminal subtype based on seven molecular classification systems in both TCGA‐BLCA and Xiangya cohorts (Figure S9A and Table S4, Supporting Information). Here, S100A5 is linked to urinary bladder cancer.